Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Nonalcoholic fatty liver disease (NAFLD) is a prevalent and increasingly diagnosed condition characterized by excessive fat accumulation in the liver. As an emerging global health concern, NAFLD has garnered considerable attention due to its close association with obesity, metabolic syndrome, type 2 diabetes, and other lifestyle-related factors. Typically asymptomatic in its early stages, NAFLD can progress to more serious conditions such as nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, or even hepatocellular carcinoma if left untreated. The exact mechanisms underlying the development of NAFLD are complex and multifactorial; however, insulin resistance plays a central role in promoting lipid deposition within hepatocytes.
1.
Inner Thoughts of Leonard Bernstein, the "Maestro".
2.
In CML Patients With New Diagnoses, STAMP Inhibitor Outperforms Imatinib and Second-Gen TKIs.
3.
Obesity linked to subsequent neoplasms in childhood cancer survivors
4.
While most cancer screenings won't prolong lives, there are still good reasons to continue screening.
5.
In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.
1.
Colon Cancer Staging: What You Need to Know
2.
Revolutionizing Cancer Treatment with Trilaciclib: How a New Drug is Transforming Outcomes
3.
Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology
4.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
5.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
2.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
3.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
4.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
5.
Should We Use DARA Up Front As First-Line Therapy in MM?
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge